AHEAD: European Feasibility Study of the Cardiovalve Transfemoral Mitral Valve System

Mitral Regurgitation Clinical Trial

— AHEAD  

Official title:

European Feasibility Study of High Surgical Risk Patients With Severe Mitral Regurgitation Treated With the Cardiovalve Transfemoral Mitral Valve System (AHEAD Study)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03339115
• Other study ID #: CP 17-02
• Status: Recruiting
• Phase: N/A
• Start date: April 23, 2018
• Est. completion date: December 31, 2029

Study information

• Verified date: February 2024
• Source: Cardiovalve Ltd.
• Contact: Nitza Shoham, VP CA&A
• Phone: +972765388142
• Email: nitza[@]cardiovalve.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the safety of the Cardiovalve Transfemoral Mitral Valve System with its associated procedure, and observe the device performance in reducing mitral regurgitation. Data collected in this clinical study will include 30-day safety and performance, and long-term clinical outcomes over a follow-up of 2 years.

Description:

The Cardiovalve offers a mitral replacement valve delivered through a transfemoral access and transseptal approach, and is intended to reduce mortality and adverse event rates in selected patients for whom surgical options are not feasible. Innovation: A truly trans femoral, trans venous delivery of the prosthetic mitral valve which minimizes procedural risk. The Cardiovalve Implant features a dual nitinol frame for robust radial strength with decoupling of the atrial flange and ventricular portion which contains 24 grasping legs designed for atraumatic anchoring of the device to the native mitral annulus. Valve leaflets are made of bovine pericardium. The Cardiovalve implant has a very low left ventricle (LV) protrusion footprint thus reducing the risk of LV outflow tract obstruction and/or interference with the LV. The Cardiovalve delivery system (DS) is designed for transfemoral delivery of the Implant with transseptal access to the left atrium. The catheter assembly is used to center the implant relative to the native mitral valve plane and align it with the left ventricual apex-to-base axis. After valve implantation, the delivery system is withdrawn.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 31, 2029
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

General Inclusion Criteria

1. Age = 18 years

2. NYHA functional II, III or ambulatory IV

3. Severe mitral regurgitation (MR grade 3-4+)

4. Subject is on optimal guideline-directed medical therapy for heart failure for at least 30 days or CRT if indicated.

5. Elevated risk for conventional open mitral valve repair or replacement surgery in the consideration of the site Heart Team (including a cardiac surgeon, a cardiologist and imaging specialist as a minimum) based on STS/Euro Score II (per MVARC Part 1), frailty and co-morbidities.

6. Able to undergo Transesophageal Echocardiography (TEE).

7. Subject understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed.

8. The subject commits to return for the scheduled post-operative follow-up visits at the hospital. Anatomical Inclusion Criteria

9. Suitable for femoral access procedure and trans septal catheterization

10. Native mitral valve geometry and size and LV outflow tract characteristics compatible with the Cardiovalve (as assessed by the independent Screening Committee) Cardiovascular Exclusion Criteria

1. Prior stroke or TIA within 3 months or Modified Rankin Scale =4 disability

2. Acute myocardial infarction within the previous 30 days

3. Any prior heart valve surgery or transcatheter mitral intervention

4. Any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 30 days

5. Rheumatic heart disease or endocarditis within the previous 3 months

6. Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or any other structural heart disease causing heart failure other than dilated cardiomyopathy of either ischemic or non-ischemic etiology

7. Existence of inferior vena cava filter or atrial septal device (contraindicating femoral access and transseptal catheterization)

8. Untreated clinically significant coronary artery disease requiring revascularization

9. Tricuspid valve disease requiring surgery or severe tricuspid regurgitation

10. Aortic or pulmonic valve disease requiring surgery

11. CRT/ICD implant within 30 days Anatomical Exclusion Criteria (assessed by pre-procedural imaging)

12. Left Ventricular Ejection Fraction (LVEF) <30%

13. LV end diastolic diameter > 70mm

14. Significant abnormalities of the mitral valve and sub-valvular apparatus.

15. Severe mitral annular or leaflets calcification

16. Left atrial or LV thrombus or vegetation

17. Severe right ventricular dysfunction

18. Severe tricuspid or aortic valve disease General Exclusion Criteria

19. Subject who is currently participating in an investigational study, other than this study

20. Hemodynamic instability defined as systolic pressure < 90mmHg or the need for inotropic support or intra-aortic balloon pump or other hemodynamic support device, or any mechanical heart assistance

21. Subject has contrast agent hypersensitivity that cannot be adequately pre-medicated, has an allergy to Nitinol alloys (nickel and titanium), or has intolerance to antiplatelet, anticoagulant, or thrombolytic medications

22. Bleeding diathesis or hypercoagulable state

23. Active peptic ulcer or active gastrointestinal bleeding

24. Pulmonary artery systolic pressure >70 mmHg

25. Patients with renal insufficiency (creatinine > 2.5 mg/dL)

26. Need for emergent or urgent surgery for any reason or any planned cardiac Surgery within the next 12 months

27. Subject with hepatic insufficiency

28. Subject has a co-morbid illness that may result in a life expectancy of less than one year

29. Active infection that requires antibiotic therapy

30. Subject is pregnant, breastfeeding or intend to become pregnant within one year

Related Conditions & MeSH terms

• Mitral Regurgitation
• Mitral Valve Disease
• Mitral Valve Insufficiency

Intervention

Device:
• Cardiovalve Transfemoral Mitral Valve
The Cardiovalve Transfemoral Mitral Valve System is intended for use symptomatic patients with severe mitral regurgitation who are at elevated risk for surgical mitral valve repair or replacement and who are anatomically eligible for transfemoral mitral valve replacement with transseptal access to the left atrium.

Locations

Country	Name	City	State
Germany	Universitätsklinikum Bonn	Bonn	Nordrhein-Westfalen
Germany	Herzzentrum der Uniklinik Köln	Köln
Germany	Studienzentrale der Medizinische Klinik II Universitäres Herzzentrum Lübeck	Lübeck
Germany	Universitaet_Mainz	Mainz
Germany	Klinikum der Universität München LMU	München
Greece	Hygea	Athens
Italy	Maria Cecilia Hospital	Cotignola
Italy	Fondazione Toscana G. Monasterio-Ospedale del Cuore	Massa
Italy	Policlinico San Donato	Milano
Italy	San Raffaele Hospital	Milano
Italy	A.O.U. Pisana	Pisa

Sponsors (3)

Lead Sponsor	Collaborator
Cardiovalve Ltd.	Meditrial Europe Ltd., Meditrial SrL

Countries where clinical trial is conducted

Germany,  Greece,  Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary safety endpoint is freedom from all-cause mortality and major adverse events	Freedom from all-cause mortality, all cause hospitalization, major adverse cardiac events (MACE), major device- or procedure- related serious adverse events	30 days, 3 Months, 6 Months, 12 Months, and 24 Months
Secondary	Technical success	Technical success: I. Absence of procedural mortality; II. Delivery and deployment of the device in the correct position and retrieval of delivery catheter, without significant mitral stenosis, LVOT obstruction or paravalvular MR documented by intraoperative imaging [Time Frame:Intraoperative]; III. Freedom from emergency surgery or reintervention related to the device or access procedure [Time Frame: 30 days]	Intraoperative, 30 Days
Secondary	Device Success	I. Absence of procedural mortality or stroke; II. Proper placement and positioning of the device; III. Freedom from unplanned surgical or interventional procedures related to the device or access procedure	Intraoperative
Secondary	Device Success	IV. Continued intended safety and performance of the device including: No evidence of structural or functional failure; No specific device-related technical failure issues and complications; Reduction in MR grade to either optimal (0+ to trace) or acceptable (reduced by at least 1 grade from baseline with no more than 2+ MR). Number of patients with reduction in MR grade from baseline	30 days, 3 Months, 6 Months, 12 Months, and 24 Months
Secondary	Patient Success	I. Device success (either optimal or acceptable) II. Patient returned to the pre-procedural setting; III. Freedom from rehospitalizations or reinterventions for the underlying condition (e.g., mitral regurgitation, worsening of heart failure); IV. Improvement from baseline in NYHA functional class Number of patients with improvement in NYHA class; V. Six minute walk test Increase in distance (m) from baseline; VI. Improvement from baseline in quality-of-life (Kansas City Cardiomyopathy Questionnaire improvement by = 10)	30 days, 3 Months, 6 Months, 12 Months, and 24 Months